caa a22 4500 445308524 CHVBK 20180317142621.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s00404-010-1571-5 doi (NATIONALLICENCE)springer-10.1007/s00404-010-1571-5 The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy [Elektronische Daten] [Lisa Abaid, Bram Goldstein, Katrina Lopez, John Micha, John Brown III, Mark Rettenmaier, Maurie Markman] Aim: We investigated if optimal surgical debulking increases tumor responsiveness to maintenance chemotherapy and improves survival in advanced ovarian cancer patients who previously attained a clinical complete response (CCR) to primary chemotherapy. Materials and methods: We retrospectively reviewed 75 advanced ovarian cancer patients, of whom 43 and 32 underwent optimal versus suboptimal cytoreduction, respectively. All patients exhibited a CCR following 6 cycles of paclitaxel and carboplatin and subsequently received maintenance chemotherapy (paclitaxel 135mg/m2; q21days). Results: The median progression free survival (PFS) for the optimally debulked patients was 35months, compared to 20months for the suboptimal population (P=0.003). Moreover, a Cox model analysis revealed that an increased number of maintenance chemotherapy cycles and optimal surgical reduction significantly correlated with favorable patient PFS (P<0.001). In regard to overall survival (OS), the patients who had optimal cytoreductive surgery exhibited improved OS results compared to the sub-optimal surgery group (42 vs. 27months; P<0.001). However, a Cox model analysis indicated that a greater number of maintenance chemotherapy cycles was a surrogate marker for improved OS (P<0.001), but surgery type was not (P>0.05). Duration of overall patient follow-up exceeds 41months. Conclusion: In advanced ovarian cancer patients who achieve a CCR following induction chemotherapy, optimal cytoreduction may confer a greater clinical benefit from a maintenance approach compared to suboptimal cytoreduction. Springer-Verlag, 2010 Gynecologic oncology nationallicence Maintenance chemotherapy nationallicence Ovarian cancer nationallicence Surgical debulking nationallicence Abaid Lisa Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut Goldstein Bram Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut Lopez Katrina Women's Cancer Research Foundation, 92663, Newport Beach, CA, USA aut Micha John Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut Brown III John Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut Rettenmaier Mark Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut Markman Maurie The University of Texas M.D. Anderson Cancer Center, 77030, Houston, TX, USA aut Archives of Gynecology and Obstetrics Springer-Verlag 283/5(2011-05-01), 1127-1131 0932-0067 283:5<1127 2011 283 404 https://doi.org/10.1007/s00404-010-1571-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00404-010-1571-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Abaid Lisa Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut NATIONALLICENCE 700 1- Goldstein Bram Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut NATIONALLICENCE 700 1- Lopez Katrina Women's Cancer Research Foundation, 92663, Newport Beach, CA, USA aut NATIONALLICENCE 700 1- Micha John Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut NATIONALLICENCE 700 1- Brown III John Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut NATIONALLICENCE 700 1- Rettenmaier Mark Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite #507, 92663, Newport Beach, CA, USA aut NATIONALLICENCE 700 1- Markman Maurie The University of Texas M.D. Anderson Cancer Center, 77030, Houston, TX, USA aut NATIONALLICENCE 773 0- Archives of Gynecology and Obstetrics Springer-Verlag 283/5(2011-05-01), 1127-1131 0932-0067 283:5<1127 2011 283 404 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer